Polymorphisms and haplotypes of the udp-glucuronosyltransferase 2b7 gene promoter s

Drug Metabolism and Disposition

Volumn 42, Issue 5, 2014, Pages 854-862

  Hu, Dong Gui ^a   Meech, Robyn ^a   Lu, Lu ^a   McKinnon, Ross A ^a   Mackenzie, Peter I ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING PROTEIN 1; GLUCURONOSYLTRANSFERASE 2B7; REGULATOR PROTEIN; UNCLASSIFIED DRUG; DNA; FIREFLY LUCIFERASE; GLUCURONOSYLTRANSFERASE; RENILLA LUCIFERIN 2 MONOOXYGENASE; UGT2B7 PROTEIN, HUMAN;

ALLELE; ARTICLE; BASE PAIRING; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; EXON; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UGT2B7 GENE; ENZYMOLOGY; GENE LINKAGE DISEQUILIBRIUM; GENETIC TRANSFECTION; GENETICS; HAPLOTYPE; HEK293 CELL LINE; HEPG2 CELL LINE; LIVER MICROSOME; MCF 7 CELL LINE; MOLECULAR CLONING; WESTERN BLOTTING;

BLOTTING, WESTERN; CLONING, MOLECULAR; DNA; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HEK293 CELLS; HEP G2 CELLS; HUMANS; LINKAGE DISEQUILIBRIUM; LUCIFERASES, FIREFLY; LUCIFERASES, RENILLA; MCF-7 CELLS; MICROSOMES, LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSFECTION;

EID: 84898793437     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056630     Document Type: Article

References (55)

1. Ahmed M, Li W, and Liang P (2013) Identification of three new Alu Yb subfamilies by source tracking of recently integrated Alu Yb elements. Mob DNA 4:25.
2. Antonaki A, Demetriades C, Polyzos A, Banos A, Vatsellas G, Lavigne MD, Apostolou E, Mantouvalou E, Papadopoulou D, and Mosialos G, et al. (2011) Genomic analysis reveals a novel nuclear factor-kB (NF-kB)-binding site in Alu-repetitive elements. J Biol Chem 286: 38768-38782.
3. Babich V, Aksenov N, Alexeenko V, Oei SL, Buchlow G, and Tomilin N (1999) Association of some potential hormone response elements in human genes with the Alu family repeats. Gene 239:341-349.
4. Batzer MA and Deininger PL (2002) Alu repeats and human genomic diversity. Nat Rev Genet 3: 370-379.
5. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
6. Bolotin E, Chellappa K, Hwang-Verslues W, Schnabl JM, Yang C, and Sladek FM (2011) Nuclear receptor HNF4a binding sequences are widespread in Alu repeats. BMC Genomics 12: 560.
7. Cheng LC, Pai TW, and Li LA (2012) Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements. Steroids 77:100-109.
8. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77.
9. Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
10. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
11. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
12. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 39-azido-39-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7 2 polymorphism. Drug Metab Dispos 31:1125-1133.
13. Cui F, Sirotin MV, and Zhurkin VB (2011) Impact of Alu repeats on the evolution of human p53 binding sites. Biol Direct 6:2.
14. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, and van den Anker J (2008) UGT2B7 promoter variant-840G.A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 83:200-202.
15. Deininger PL, Moran JV, Batzer MA, and Kazazian HH, Jr (2003) Mobile elements and mammalian genome evolution. Curr Opin Genet Dev 13:651-658.
16. Djebli N, Picard N, Rérolle JP, Le Meur Y, and Marquet P (2007) Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 17:321-330.
17. Duguay Y, Báár C, Skorpen F, and Guillemette C (2004) A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75:223-233.
18. Ebihara M, Ohba H, Ohno SI, and Yoshikawa T (2002) Genomic organization and promoter analysis of the human nicotinic acetylcholine receptor alpha6 subunit (CHNRA6) gene: Alu and other elements direct transcriptional repression. Gene 298:101-108.
19. Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, and Wrighton SA (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727-739.
20. Fladvad T, Klepstad P, Langaas M, Dale O, Kaasa S, Caraceni A, and Skorpen F (2013) Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain. Pharmacogenet Genomics 23:117-126.
21. Hess J, Angel P, and Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117:5965-5973.
22. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, and Shimizu E, et al. (2003) Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31: 677-680.
23. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE, and Skorpen F (2002) Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1 28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353-356.
24. Holthe M, Rakvåg TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, and Skorpen F (2003) Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3:17-26.
25. Hu DG and Mackenzie PI (2009) Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. Mol Pharmacol 76:425-439.
26. Hu DG and Mackenzie PI (2010) Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells. Drug Metab Dispos 38:2105-2109.
27. Hwang MS, Lee SJ, Jeong HE, Lee S, Yoo MA, and Shin JG (2010) Genetic variations in UDPglucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population. Drug Metab Pharmacokinet 25:398-402.
28. Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, and Das S, et al. (2008) Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 18:683-697.
29. Ishii Y, Hansen AJ, and Mackenzie PI (2000) Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 57:940-947.
30. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
31. Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C, and Martin C (2012) Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol 87:534-536.
32. Kaer K and Speek M (2013) Retroelements in human disease. Gene 518:231-241.
33. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, and Miners JO (2009) Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDPglucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos 37:1948-1955.
34. Klepstad P, Kaasa S, and Borchgrevink PC (2000) Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 55:713-719.
35. Le Goff W, Guerin M, Chapman MJ, and Thillet J (2003) A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression. J Lipid Res 44:902-910.
36. Li Y, Bolten C, Bhat BG, Woodring-Dietz J, Li S, Prayaga SK, Xia C, and Lala DS (2002) Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol Endocrinol 16:506-514.
37. Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, Ma QW, Lu DR, and Shen JH (2005) An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 85:502-506.
38. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, and Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48:236-244.
39. Ménard V, Eap O, Roberge J, Harvey M, Lévesque E, and Guillemette C (2011) Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants. Pharmacogenet Genomics 21:631-641.
40. Ménard V, Lévesque E, Chen S, Eap O, Joy MS, Ekström L, Rane A, and Guillemette C (2013) Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer. Pharmacogenet Genomics 23:684-696.
41. Nakamura A, Nakajima M, Higashi E, Yamanaka H, and Yokoi T (2008) Genetic polymorphisms in the 59-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet Genomics 18:709-720.
42. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, and Reynolds WF (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412-14420.
43. Polak P and Domany E (2006) Alu elements contain many binding sites for transcription factors and may play a role in regulation of developmental processes. BMC Genomics 7:133.
44. Price AL, Eskin E, and Pevzner PA (2004) Whole-genome analysis of Alu repeat elements reveals complex evolutionary history. Genome Res 14:2245-2252.
45. Radominska-Pandya A, Little JM, and Czernik PJ (2001) Human UDP-glucuronosyltransferase 2B7. Curr Drug Metab 2:283-298.
46. Roy-Engel AM, Carroll ML, Vogel E, Garber RK, Nguyen SV, Salem AH, Batzer MA, and Deininger PL (2001) Alu insertion polymorphisms for the study of human genomic diversity. Genetics 159:279-290.
47. Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Ueno K, Kamakura S, Kamatani N, and Komamura K, et al. (2004) Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048-1054.
48. Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, and Owada E, et al. (2006) Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39:303-308.
49. Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, and Boyett JM,, et al. (2003) A pharmacogenetic study of uridine diphosphateglucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566-574.
50. Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, and Perusse L, et al. (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66:125-133.
51. Tian JN, Ho IK, Tsou HH, Fang CP, Hsiao CF, Chen CH, Tan HK, Lin L, Wu CS, and Su LW, et al. (2012) UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics 13:879-888.
52. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, and Foley KM (1995) Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 61: 47-54.
53. Turker MS and Bestor TH (1997) Formation of methylation patterns in the mammalian genome. Mutat Res 386:119-130.
54. Vansant G and Reynolds WF (1995) The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. Proc Natl Acad Sci USA 92:8229-8233.
55. Wiener D, Doerge DR, Fang JL, Upadhyaya P, and Lazarus P (2004) Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32:72-79.